cancer confirming recent cDNA expression analyses.
Int J Cancer 2005;116:340–350.
8 Abd El-Rehim DM, Pinder SE, Paish CE, et al.
Expression of luminal and basal cytokeratins in human
breast carcinoma. J Pathol 2004;203:661–671.
9 Livasy CA, Karaca G, Nanda R, et al. Phenotypic
evaluation of the basal-like subtype of invasive breast
carcinoma. Mod Pathol 2006;19:264–271.
10 van de Rijn M, Perou CM, Tibshirani R, et al.
Expression of cytokeratins 17 and 5 identifies a group
of breast carcinomas with poor clinical outcome. Am J
11 Banerjee S, Reis-Filho JS, Ashley S, et al. Basal-like
breast carcinomas: clinical outcome and response to
chemotherapy. J Clin Pathol 2006;59:729–735.
12 Gamallo C, Moreno-Bueno G, Sarrio D, et al. The
prognostic significance of P-cadherin in infiltrating
ductal breast carcinoma. Mod Pathol 2001;14:650–654.
13 Rouzier R, Perou CM, Symmans WF, et al. Breast
cancer molecular subtypes respond differently to
preoperative chemotherapy. Clin Cancer Res 2005;11:
14 Rodriguez-Pinilla SM, Sarrio D, Honrado E, et al.
Prognostic significance of basal-like phenotype and
fascin expression in node-negative invasive breast
carcinomas. Clin Cancer Res 2006;12:1533–1539.
15 Palacios J, Benito N, Pizarro A, et al. Anomalous
expression of P-cadherin in breast carcinoma. Correla-
tion with e-cadherin expression and pathological
features. Am J Pathol 1995;146:605–612.
16 Rakha EA, Putti TC, Abd El-Rehim DM, et al.
Morphological and immunophenotypic analysis of
breast carcinomas with basal and myoepithelial differ-
entiation. J Pathol 2006;208:495–506.
17 Tsuda H, Takarabe T, Hasegawa F, et al. Large, central
acellular zones indicating myoepithelial tumor differ-
entiation in high-grade invasive ductal carcinomas as
markers of predisposition to lung and brain metas-
tases. Am J Surg Pathol 2000;24:197–202.
18 Fulford LG, Easton DF, Reis-Filho JS, et al. Specific
morphological features predictive for the basal pheno-
type in grade 3 invasive ductal carcinoma of breast.
19 Reis-Filho JS, Milanezi F, Steele D, et al. Metaplastic
breast carcinomas are basal-like tumours. Histopatho-
20 Jacquemier J, Padovani L, Rabayrol L, et al. Typical
medullary breast carcinomas have a basal/myoepithe-
lial phenotype. J Pathol 2005;207:260–268.
21 Laakso M, Loman N, Borg A, et al. Cytokeratin 5/14-
positive breast cancer: true basal phenotype confined
to BRCA1 tumors. Mod Pathol 2005;18:1321–1328.
22 Foulkes WD, Brunet JS, Stefansson IM, et al. The
prognostic implication of the basal-like (cyclin E high/
tion+) phenotype of BRCA1-related breast cancer.
Cancer Res 2004;64:830–835.
23 Turner N, Reis-Filho JS. Basal-like breast cancer
and the BRCA1 phenotype. Oncogene 2006;25:5846–
24 Palacios J, Honrado E, Osorio A, et al. Re: Germline
BRCA1 mutations and a basal epithelial phenotype in
breast cancer. J Natl Cancer Inst 2004;96:712–714;
author reply 4.
25 Robson ME, Chappuis PO, Satagopan J, et al. A
combined analysis of outcome following breast cancer:
differences in survival based on BRCA1/BRCA2 muta-
tion status and administration of adjuvant treatment.
Breast Cancer Res 2004;6:R8–R17.
26 Chappuis PO, Goffin J, Wong N, et al. A significant
response to neoadjuvant chemotherapy in BRCA1/2
related breast cancer. J Med Genet 2002;39:608–610.
27 Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCA-
ness’ in sporadic cancers. Nat Rev Cancer 2004;4:
28 Turner N, Reis-Filho JS, Russel AM, et al. BRCA1
down-regulation in sporadic basal-like breast cancer.
29 Graham V, Khudyakov J, Ellis P, et al. Sox2 functions to
maintain neural progenitor identity. Neuron
30 D’Amour KA, Gage FH. Genetic and functional
differences between multipotent neuronal and plur-
ipotent embryonic stem cells. Proc Natl Acad Sci USA
31 Chickarman V, Troein C, Nuber UA, et al. Transcrip-
tional dynamics of the embryonic stem cell switch.
PLoS Comput Biol 2006;2:1080–1092.
32 Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous
stem cells can arise from pediatric brain tumors. Proc
Natl Acad Sci USA 2003;9:15178–15183.
33 Carlin R, Davis D, Weiss M, et al. Expression of early
transcription factors Oct4, Sox2 and Nanog by porcine
umbilical cord (PUC) matrix cells. Reprod Biol
34 Katoh Y, Katoh M. Comparative genomics on SOX2
orthologs. Oncol Rep 2005;14:797–800.
35 Kuroda T, Tada M, Kubota H, et al. Octamer and Sox
elements are required for transcriptional cis regulation
of Nanog gene expression. Mol Cell Biol 2005;25:
36 Chew JL, Loh YH, Zhang W, et al. Reciprocal
transcriptional regulation of Pou5f1 and Sox2 via the
Oct4/Sox2 complex in embryonic stem cells. Mol Cell
37 Mansukhani A, Ambrosetti D, Holmes G, et al. Sox2
induction by FGF and FGFR2 activating mutations
inhibits Wnt signaling and osteoblast differentiation.
J Cell Biol 2005;168:1065–1076.
38 Takemoto T, Uchikawa M, Kamachi Y, et al. Conver-
gence of Wnt and FGF signals in the genesis of
posterior neural plate through activation of the sox2
enhancer N-1. Development 2006;133:297–306.
39 Korkola JE, Houldsworth J, Chadalavada RSV, et al.
Down-regulation of stem cell genes, including those in
a 200-kb gene cluster at 12p13.3, is associated with in
vivo differentiation of human male germ cell tumors.
Cancer Res 2006;66:820–827.
40 Rao M. Conserved and divergent paths that regulate
self-renewal in mouse and human embryonic stem
cells. Dev Biol 2004;275:269–286.
41 van Raag TJ, Moore KB, Iordanova I, et al. Frizzled 5
signaling governs the neural potential of progenitors
in the developing Xenopus retina. Neuron 2005;46:
42 Wessels LF, van Welsem T, Hart AA, et al. Molecular
classification of breast carcinomas by comparative
genomic hybridization: a specific somatic genetic pro-
file for BRCA1 tumors. Cancer Res 2002;62:7110–7117.
43 van Beers EH, van Welsem T, Wessels LF, et al.
Comparative genomic hybridization profiles in human
BRCA1 and human BRCA2 breast tumors highlight
differential sets of genomic aberrations. Cancer Res
SOX2 in sporadic basal-like breast cancer
SM Rodriguez-Pinilla et al
Modern Pathology (2007) 20, 474–481